Opioid-Sparing Regimens Face High Hurdles After US FDA Advisory Cmte.

Panelists felt the phrase "opioid sparing" was too broad, and contended that it is difficult to develop a non-opioid alternative without an opioid as an active comparator. 

FDA Advisory Committee Feature image

The US FDA has floated a variety of policies to combat the opioid epidemic in recent years, but addressing the crisis through opioid-sparing outcomes and the development of substitutable, non-opioid drugs may be the most difficult options to pursue following a series of votes from the agency's Anesthetic and Analgesic Drug Products Advisory Committee on Nov. 15.

Committee members encouraged FDA to adopt a high regulatory bar on both fronts. The panel voted 11-1, with one abstention,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers